Department of Pharmacy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00507-18. Print 2018 Sep.
Intravenous voriconazole (VRC) is formulated by the incorporation of sulfobutylether-β-cyclodextrin (SBECD), which may accumulate to adversely affect renal function. However, the effect of long-term use of intravenous VRC on renal function is unclear. Our retrospective analysis of data confirmed that worsening of renal function was significantly associated with a cumulative dose of intravenous VRC (≥400 mg/kg), suggesting that a higher cumulative dose of intravenous VRC is a risk factor for renal dysfunction.
静脉注射伏立康唑（VRC）通过磺丁基醚-β-环糊精（SBECD）的加入来配制，这可能会蓄积并对肾功能产生不良影响。然而，长期使用静脉 VRC 对肾功能的影响尚不清楚。我们对数据的回顾性分析证实，肾功能恶化与静脉 VRC 的累积剂量（≥400mg/kg）显著相关，提示静脉 VRC 的更高累积剂量是肾功能障碍的一个危险因素。
